BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 11196154)

  • 1. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T; Martuza RL; Dallman MJ; Rabkin SD
    Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
    Liu A; Hu P; Khawli LA; Epstein AL
    Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy.
    Ino Y; Saeki Y; Fukuhara H; Todo T
    Clin Cancer Res; 2006 Jan; 12(2):643-52. PubMed ID: 16428511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
    Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
    Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules.
    Katsanis E; Xu Z; Bausero MA; Dancisak BB; Gorden KB; Davis G; Gray GS; Orchard PJ; Blazar BR
    Cancer Gene Ther; 1995 Mar; 2(1):39-46. PubMed ID: 7542553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.
    Fukuhara H; Ino Y; Kuroda T; Martuza RL; Todo T
    Cancer Res; 2005 Dec; 65(23):10663-8. PubMed ID: 16322208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
    Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
    Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
    Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
    Xiang J; Chen Y; Moyana T
    Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant.
    Sturmhoefel K; Lee K; Gray GS; Thomas J; Zollner R; O'Toole M; Swiniarski H; Dorner A; Wolf SF
    Cancer Res; 1999 Oct; 59(19):4964-72. PubMed ID: 10519410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors.
    Iwadate Y; Yamaura A; Sato Y; Sakiyama S; Tagawa M
    Cancer Res; 2001 Dec; 61(24):8769-74. PubMed ID: 11751397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.
    Toda M; Iizuka Y; Kawase T; Uyemura K; Kawakami Y
    Cancer Gene Ther; 2002 Apr; 9(4):356-64. PubMed ID: 11960286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity.
    Toda M; Martuza RL; Kojima H; Rabkin SD
    J Immunol; 1998 May; 160(9):4457-64. PubMed ID: 9574551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules.
    Moro M; Gasparri AM; Pagano S; Bellone M; Tornaghi P; Veglia F; Corti A; Casorati G; Dellabona P
    Cancer Res; 1999 Jun; 59(11):2650-6. PubMed ID: 10363988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma.
    Tatsumi T; Takehara T; Kanto T; Kuzushita N; Ito A; Kasahara A; Sasaki Y; Hori M; Hayashi N
    Hepatology; 1999 Aug; 30(2):422-9. PubMed ID: 10421650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.
    Ali SA; McLean CS; Boursnell ME; Martin G; Holmes CL; Reeder S; Entwisle C; Blakeley DM; Shields JG; Todryk S; Vile R; Robins RA; Rees RC
    Cancer Res; 2000 Mar; 60(6):1663-70. PubMed ID: 10749137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
    Lee YS; Kim JH; Choi KJ; Choi IK; Kim H; Cho S; Cho BC; Yun CO
    Clin Cancer Res; 2006 Oct; 12(19):5859-68. PubMed ID: 17020994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma.
    Sandler AD; Chihara H; Kobayashi G; Zhu X; Miller MA; Scott DL; Krieg AM
    Cancer Res; 2003 Jan; 63(2):394-9. PubMed ID: 12543793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intramuscular gene transfer of soluble B7.1/IgG(1) fusion cDNA induces potent antitumor immunity as an adjuvant for DNA vaccination.
    Zhou ZF; Peretz Y; Chang Y; Miao DS; Li X; Prud'homme GJ
    Cancer Gene Ther; 2003 Jun; 10(6):491-9. PubMed ID: 12768195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.